Common denial reasons include insufficient BMI documentation, missing lifestyle modification records, or not trying required step therapy first
Section 1847A(i)(5) of the Act requires that for Part B rebatable drugs, as defined in section 1847A(i)(2)(A) of the Act, furnished on or after April 1, 2023, in quarters in which the payment amount described in section 1847A(i)(3)(A)(ii)(I) of the Act (or, in the case of selected drugs described under section 1192(c) of the Act, the payment amount described in section 1847A(b)(1)(B) of the Act), exceeds the inflation-adjusted payment amount determined in accordance with section 1847A(i)(3)(C) of the Act, the coinsurance will be 20 percent of the inflation-adjusted payment amount for such quarter (hereafter, the inflation-adjusted coinsurance amount)
[43] Synthesis [edit] The synthesis of tirzepatide was first disclosed in patents filed by Eli Lilly and Company in 2016
Whether you are coming in on a lunch break from the DTC or scheduling around school pickup, the team works with your life, not against it